Schistosoma mansoni Stomatin Like Protein-2 Is Located in the Tegument and Induces Partial Protection against Challenge Infection by Farias, Leonardo P. et al.
Schistosoma mansoni Stomatin Like Protein-2 Is Located
in the Tegument and Induces Partial Protection against
Challenge Infection
Leonardo P. Farias
1, Fernanda C. Cardoso
2, Patricia A. Miyasato
1, Bogar O. Montoya
1, Cibele A.
Tararam
1, Henrique K. Roffato
1, Toshie Kawano
1, Andrea Gazzinelli
3, Rodrigo Correa-Oliveira
4,
Patricia S. Coulson
5, R. Alan Wilson
5,S e ´rgio C. Oliveira
2, Luciana C. C. Leite
1*
1Centro de Biotecnologia, Instituto Butantan, Sa ˜o Paulo, SP, Brazil, 2Departmento de Bioquı ´mica e Imunologia, Instituto de Cie ˆncias Biolo ´gicas, Universidade Federal de
Minas Gerais, Belo Horizonte, MG, Brazil, 3Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil, 4Laborato ´rio de Imunologia e
Biologia Molecular, Centro de Pesquisas Rene ´ Rachou (CPqRR), Fiocruz, Belo Horizonte, MG, Brazil, 5Department of Biology, University of York, York, United Kingdom
Abstract
Background: Schistosomiasis affects more than 200 million individuals worldwide, with a further 650 million living at risk of
infection, constituting a severe health problem in developing countries. Even though an effective treatment exists, it does
not prevent re-infection, and the development of an effective vaccine still remains the most desirable means of control for
this disease.
Methodology/Principal Findings: Herein, we report the cloning and characterization of a S. mansoni Stomatin-like protein 2
(SmStoLP-2). In silico analysis predicts three putative sites for palmitoylation (Cys11, Cys61 and Cys330), which could
contribute to protein membrane association; and a putative mitochondrial targeting sequence, similar to that described for
human Stomatin-like protein 2 (HuSLP-2). The protein was detected by Western blot with comparable levels in all stages
across the parasite life cycle. Fractionation by differential centrifugation of schistosome tegument suggested that SmStoLP-
2 displays a dual targeting to the tegument membranes and mitochondria; additionally, immunolocalization experiments
confirm its localization in the tegument of the adult worms and, more importantly, in 7-day-old schistosomula. Analysis of
the antibody isotype profile to rSmStoLP-2 in the sera of patients living in endemic areas for schistosomiasis revealed that
IgG1, IgG2, IgG3 and IgA antibodies were predominant in sera of individuals resistant to reinfection as compared to those
susceptible. Next, immunization of mice with rSmStoLP-2 engendered a 30%–32% reduction in adult worm burden.
Protective immunity in mice was associated with specific anti-rSmStoLP-2 IgG1 and IgG2a antibodies and elevated
production of IFN-c and TNF-a, while no IL-4 production was detected, suggesting a Th1-predominant immune response.
Conclusions/Significance: Data presented here demonstrate that SmStoLP-2 is a novel tegument protein located in the
host-parasite interface. It is recognized by different subclasses of antibodies in patients resistant and susceptible to
reinfection and, based on the data from murine studies, shows protective potential against schistosomiasis. These results
indicate that SmStoLP-2 could be useful in a combination vaccine.
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Introduction
Schistosomiasis is an important parasitic disease, caused by
trematode worms of the genus Schistosoma; it affects approximately
200 million of individuals primarily in developing countries and an
estimated additional 500 to 600 million are at risk. The digenetic
blood fluke, Schistosoma mansoni, is one of the major causative agents
[1]. Parasite eggs are trapped in the liver and intestine, where they
induce granuloma formation and fibrosis, the main cause of
morbidity and mortality in schistosomiasis [2]. Chemotherapy is
an important control strategy against this parasitic disease [3];
however, it has not reduced the endemicity [4] and rapid
reinfection demands frequent treatment [5]. Therefore, it is
considered that an effective vaccine combined with chemotherapy
would be an efficient control mechanism [6].
Until October 2003, schistosome research suffered from limited
genomic information; this situation has changed significantly with
the simultaneous publication of the S. mansoni and S. japonicum
transcriptomes [7,8]. These initiatives, together with the advent of
entire S. mansoni genome sequencing, all boosted by advances in
bioinformatics, have markedly changed the schistosome vaccine
research field. Simultaneously with the publication of the
transcriptome data, and its scrutiny for genes with functions that
would indicate their surface exposure to allow interaction with the
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potential vaccine candidates based on their functional classifica-
tion by Gene Ontology [8]. One of these, stomatin, was assigned a
role in lipid raft formation or receptor binding by Gene Ontology
categorization. Actually, it is most similar to the sub-family
Stomatin Like Protein 2 (SLP-2), of which the best characterized
gene is the human ortholog [9]. The protein was also proposed as
a schistosome drug target [8], since the human ortholog was
described as interacting with anti-malarial drugs, participating in
the transfer of the drug Mefloquine to the intracellular parasite via
a pathway used for the uptake of exogenous phospholipids [10].
The SLP-2 was first identified in humans (HuSLP-2); it presents,
like other stomatins (e.g. Stomatin, SLP-1 and SLP-3), a central
Stomatin, Prohibitin, Flotillin, HflK/C (SPFH) domain that may
mediate interactions with plasma and mitochondrial membranes
[11–13]. HuSLP-2 is the first member of this family that lacks an
N-terminal hydrophobic domain, displaying a mitochondrial
targeting sequence in this region. Additionally, a palmitoylation
centered on Cys29 could not be identified [9,11]. The function of
stomatins, including SLP-2, remains undetermined. In erythro-
cytes, it may link stomatin or other integral membrane proteins to
the peripheral cytoskeleton, playing a role in the regulation of ion
channel conductance or in the organization of sphingolipids and
cholesterol-rich lipid rafts [9]. More recently, this gene has been
investigated as a novel cancer-related gene over-expressed in
certain kinds of human tumours [14,15], and in the assembly of
mechanosensation receptors [16–22]. Moreover, it has been
proposed to function as a link between synapse-polarized
mitochondria and T-cell receptor (TCR) signalosomes, contribut-
ing to modulate TCR signalling and T cell activation [23,24].
In this work, we describe and characterize a novel S. mansoni
stomatin like protein 2 (SmStoLP-2). Data obtained here
establishes that SmStoLP-2 is present in the tegument of adult
worms and schistosomula. In addition, we evaluated the reactivity
of rSmStoLP-2 antigen against the sera from individuals living in
endemic areas for schistosomiasis in Brazil, showing that the
groups resistant and susceptible to reinfection showed different
antibody profiles. We subsequently demonstrated the ability of
anti-rSmStoLP-2 serum to inhibit penetration and migration of
cercariae in vivo. Lastly, immunization of mice with rSmStoLP-2
induced a Th1-type of immune response and a significant
reduction in worm burden upon challenge with cercariae.
Materials and Methods
Parasite maintenance
Schistosoma mansoni adult worms (BH strain) were obtained by
perfusion of mice, 7–8 weeks after infection. Eggs, miracidia,
cercariae, and schistosomula were obtained as previously de-
scribed [8]. Cercaria number and viability were determined using
a light microscope prior to infection.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Fundac ¸a ˜o Oswaldo Cruz (0083/99-
CEP/FIOCRUZ). All patients or their legal guardians provided
written informed consent for the collection of samples and
subsequent analysis.
All animals were handled in strict accordance with good animal
practice as defined by Animals Use Ethics Committee of UFMG
(Universidade Federal de Minas Gerais, Brazil) and Instituto
Butantan (Sa ˜o Paulo, Brazil), and the study was conducted
adhering to the institution’s guidelines for animal husbandry.
Study population
Peripheral blood was obtained from individuals with different
genetic background living in three endemic areas for schistosomi-
asis (‘Melquiades’, ‘Caatinga do Moura’ and ‘Co ˆrrego do Onc ¸a’,
all in the state of Minas Gerais, Brazil). These individuals were
classified in four groups according to their infection status and the
selection of subjects was performed based only on the criteria for
inclusion and exclusion of each group independent of previous
knowledge of immune responses for each individual. Non-infected
(NI) individuals are healthy people from non-endemic areas
without any parasite infection or contact with contaminated water.
One group was shown to be stool-negative after treatment with
praziquantel and was classified as resistant to S. mansoni reinfection
(RR) [25]. The water contact exposure was determined using
previously described methods [26–28], objectively evaluated by
observers and studied population had at least one contact daily.
Individuals classified as susceptible to S. mansoni reinfection (SR)
were shown to be stool-positive following treatment with
praziquantel (40 mg/kg) (at 1 and 5 months). The sera from RR
and SR groups were obtained six months after praziquantel
treatment and these individuals were examined for S. mansoni
infections using the Kato–Katz technique before treatment and
one, 6 and 12 months after treatment to check for reinfection rates
[25]. Individuals grouped as infected (INF) showed stool-positive
examination and no treatment history (never received anti-
helminthic treatment, as determined by survey). These infected
patients had infection levels that varied from 48 to 224 epg (egg
counts per gram of feces). For each time point, three independent
(consecutive days) stool samples were taken and two slides were
prepared from each sample. These patients or their legal
guardians gave informed consent after explanation of the protocol
that had been previously approved by the Ethical Committee of
Fundac ¸a ˜o Oswaldo Cruz. Details regarding sex and age of the
individuals included in this study are described in Table S1.
Author Summary
Schistosomiasis is a parasitic disease causing serious
chronic morbidity in tropical countries. Together with the
publication of the transcriptome database, a series of new
vaccine candidates were proposed based on their func-
tional classification. However, the prediction of vaccine
candidates from sequence information or even by
proteomics or microarrays data is somewhat speculative
and there remains the considerable task of functional
analysis of each new gene/protein. In this study, we
present the characterization of one of these molecules, a
stomatin like protein 2 (SmStoLP-2). Sequence analysis
predicts signals that could contribute to protein mem-
brane association and mitochondrial targeting, which was
confirmed by differential extractions of schistosome
tegument membranes and mitochondria. Additionally,
confocal microscope analysis showed SmStoLP-2 present
in the tegument of 7-day-old schistosomula and adult
worms. Studies in patients living in endemic areas for
schistosomiasis revealed high levels of IgG1, IgG2, IgG3
and IgA anti-SmStoLP-2 antibodies in individuals resistant
to reinfection. Recombinant SmStoLP-2 protein, when
used as vaccine, induced significant levels of protection
in mice. This reduction in worm burden was associated
with a typical Th1-type immune response. These results
indicate that SmStoLP-2 could be useful in association with
other antigens for the composition of a vaccine against
schistosomiasis.
SmStoLP-2: A Schistosoma Tegument Protein
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Total RNA was isolated from adult worms (1 g) using TRIzol
reagent (Invitrogen), followed by mRNA purification with oligo
(dT)-cellulose columns according to the manufacturer’s instruc-
tions (Amersham Biosciences). The SuperScript
TM plasmid system
for cDNA synthesis and cloning (Invitrogen) was used for cDNA
library construction following the manufacturer’s protocol. The
cDNA fragments were directionally ligated into the SalI/NotI
cloning sites of the pSPORT1 vector and transformed into
competent Escherichia coli DH5a.
Specific oligonucleotides were designed using the EST assembly
partial sequence from the Sa ˜o Paulo Transcriptome data (SmAE
606856.1, http://bioinfo.iq.usp.br/schisto6/) together with an
EST from TIGR (BF936634). The 59 and 39 oligonucleotides,
CACCATGATTCGTAGTATCATTGG and CTATTCTTG-
TTTATCGCTATC, were used in a PCR reaction to amplify
the complete open reading frame of SmStoLP-2 from a cDNA
library made from adult worms. The PCR reaction was performed
using Platinum Pfx enzyme (Invitrogen), and initiated with one
cycle of 5 min at 94uC, followed by 30 cycles of 30 s at 94uC,
1 min at 55uC, and 3 min at 68uC. PCR products were purified
from agarose gel electrophoresis, cloned into pENTR/D TOPO
cloning vector (Invitrogen), and sequenced to confirm its identity.
Phylogenetic and sequence analysis
Blast and PSI-Blast searches against the non-redundant protein
sequence database, using SmStoLP-2 as a query, were used to
identify orthologs of SmStoLP-2. Additionally, we searched the S.
mansoni genome (GeneDB, http://www.genedb.org/genedb/
smansoni/) for proteins with Pfam SPFH/Band 7 domains. Post-
translational modification prediction: the signal peptide prediction
was performed using the SignalP 3.0 server (http://www.cbs.dtu.
dk/services/SignalP/), transmembrane helices were analyzed
by TMHMM version 2.0 (http://www.cbs.dtu.dk/services/
TMHMM-2.0/), palmitoylation sites were predicted by CSS-
Palm (http://csspalm.biocuckoo.org/1.0/index.php) [29], and
mitochondrial targeting sequence as predicted by the MitoProt
program (http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.
html). Molecular weight (MW) and isoelectric point (pI) were
calculated with the Compute pI/Mw tool (http://www.expasy.
ch/tools/pi_tool.html).
For phylogenetic analyses, alignments of protein sequences were
performed using the ClustalX 1.83 software. The tree was
constructed using Clustal with the Neighbour Joining method,
excluding positions with gaps. The numbers represent the
confidence of the branches assigned by bootstrap (in 1000
samplings). The TreeView program (http://taxonomy.zoology.
gla.ac.uk/rod/treeview.html) was used to visualize the tree.
Expression of recombinant protein and polyclonal
antibody production
To produce a recombinant SmStoLP-2, the full-length cDNA
sequence was directionally cloned by recombination into
pDEST17 (to produce a protein that contains an N-terminal
hexahistidine tag) and transformed into BL21 (DE3) (Invitrogen).
For protein expression, the transformed cells were grown in
600 ml LB plus ampicilin (OD600=0.6). Isopropyl-b-D-thiogalac-
topyranoside (IPTG) was added to the culture to a final
concentration of 1 mM, and cells were incubated for 3–4 h at
37uC. Cells were harvested by centrifugation and resuspended in
50 ml of lysis buffer (50 mM sodium phosphate pH 8.3, 0.3 M
NaCl). The cell suspension was passed twice (1500 psi) through a
French press and the crude homogenate was centrifuged at
20,0006g for 40 min. The pelleted inclusion bodies were washed
twice with wash buffer (lysis buffer, 2% Triton X-100, 2 M urea)
and finally resuspended in solubilization buffer (lysis buffer, 5 mM
beta-mercaptoethanol, 20 mM imidazole, 8 M urea). The recom-
binant protein was refolded from the inclusion bodies by diluting
100-fold into equilibration buffer (solubilization buffer without
urea).
The recombinant protein was then purified by metal affinity
chromatography using the Akta Prime system (Amersham
Biosciences) under native conditions. Briefly, the sample was
loaded onto a Ni
2+-NTA column (5 ml bed volume) pre-
equilibrated with the same buffer. The column was washed with
10 bed volumes of the equilibration buffer and then eluted with
20–500 mM imidazole linear gradient. The main peak was pooled
and the protein purity of fractions was assessed using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Further, the elution buffer was exchanged with Phosphate Buffer
Saline pH 7.4 (PBS) before use of this protein.
Polyclonal rat serum was produced against preparations of
recombinant SmStoLP-2. Rodents were inoculated four times, at
21-day intervals with 100 mg of protein mixed with TiterMax
adjuvant (CytRx Corporation; first dose) or PBS (in subsequent
doses). Fifteen days after the last inoculation, rodents were
exsanguinated. The sera were used at a dilution of 1:10,000 (v:v)
in Western blots and 1:100 in indirect immunofluorescence assays.
Circular dichroism (CD) measurements
CD measurements were carried out on a Jasco J-810
Spectropolarimeter at 20uC equipped with a Peltier unit for
temperature control. Far-UV CD spectrum was acquired using a
1 mm path length cell at 0.5 nm intervals over the wavelength
range from 190 to 260 nm. Five scans were averaged for each
sample and subtracted from the blank average spectra. The
protein concentration was kept at 10 mM in 10 mM sodium
phosphate buffer pH 7.4.
Protein expression profile
Total parasite extracts from eggs, miracidia, cercariae, 10-day
old schistosomula and adult worms of S. mansoni were prepared in
40 mM Tris, pH 7.4, 2% SDS plus protease inhibitor cocktail
(Sigma) through sonication (4 cycles of 2 min, with pulses of
0.75 s, 40% amplitude). The samples were centrifuged at
20,0006g for 30 min at 4uC and the supernatant was quantified
and used for assays. The soluble fraction of adult worms and
schistosomula was obtained in a similar way, with the exception of
2% SDS in the sonication buffer. After centrifugation at 20,0006g
for 30 min at 4uC, the supernatant was recovered, and the
insoluble pellet was sonicated in the presence of 2% SDS, which
after centrifugation at 20,0006g for 30 min at 4uC, originated the
so-called insoluble fraction. Their protein concentrations were
determined with a RC DC Protein Assay Kit (Bio-Rad, CA, USA).
Samples of purified rSmStoLP-2 and extracts (20 mg) were
submitted to SDS-PAGE. The gel was electroblotted onto a
PVDF membrane, which was blocked with 0.02 M Tris (pH 7.5)
and 0.3% Tween 20 containing 5% dry milk for 16 h at 4uC.
Subsequently, the membrane was incubated in a 1:10,000 dilution
with primary antibody in blocking buffer plus 150 mM NaCl for
3 h at room temperature. After three washes using Tris 10 mM
(pH 7.5), the membrane was incubated in a 1:4000 dilution with
secondary goat anti-rat IgG conjugated to horseradish peroxidase
(HRP) (Pierce) for 1 h and after three washes using Tris 10 mM
(pH 7.5), the membrane was treated with ECL plus (GE) reagent
according to manufacturer’s instructions.
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fractionation: Surface membranes and mitochondrial
enrichment
The sample used in this experiment was kindly provided by Dr.
Simon Braschi (University of York, England, UK). Briefly, the
tegument was removed by a freeze/thaw method and surface
membranes enriched by sucrose-gradient centrifugation as previ-
ously described [30,31], generating a gradient pellet. Proteins were
sequentially extracted from the gradient pellet using a three-step
process with reagents of increasing solubilizing power as follows:
Extract 1 (soluble proteins): 40 mM Tris, pH 7.4; Extract 2 (non-
covalent, but firmly bound proteins): 5 M urea (BDH, VWR
International, Dorset, UK), 2 M thiourea (BDH) in 40 mM Tris,
pH 7.4 (Extraction Buffer 2; EB2); Extract 3 (GPI-anchored and
single membrane spanners): EB2 plus 4% CHAPS (Sigma) and
2% N-decyl-N, N-dimethyl-3-ammonio-1-propane sulphate (SB
3–10; Sigma), pH 7.4; Final pellet (multispanning membrane
proteins): solubilized with 40 mM Tris, pH 7.4 plus 2% SDS.
Mitochondrial enriched fraction was prepared from adult worm
tegument in isotonic mitochondrial buffer (MB) (210 mM mannitol,
70 mM sucrose, 1 mM EDTA, 10 mM HEPES pH 7.5) supple-
mented with complete protease inhibitor cocktail (Sigma). The
tegument membranes were obtained by centrifugation at 1006g for
30 min at 4uC. The resulting supernatant was centrifuged at
10,0006g for 10 min at 4uC to purify the mitochondrial fraction.
Theresultingpelletswereressuspended in40 mMTris,pH 7.4plus
2% SDS. The protein concentration was estimated by the method
of Lowry with a RC DC Protein Assay Kit (Bio-Rad, CA, USA).
Anti-Mitofusin-1 antibody (Mfn1 (H-65) (Santa Cruz Biotechnol-
ogy) (1:200 dilution) was used as a mitochondrial tracker in Western
blot experiments followed by incubation with secondary goat anti-
rabbit IgG conjugated to HRP (Sigma).
Indirect immunofluorescence and confocal microscopy
Freshly perfused worms were embedded in OCT medium in a
pre-cooled beaker of isopentene, frozen in liquid N2. Eight-
micrometer cryostat adult worm sections were adhered to silanized
glass slides (DakoCytomation) and fixed in acetone for 30 min at
220uC before blocking with PNT (PBS 1x, 10% Naive rabbit
serum and 0.1% Tween 20) for 4 h at room temperature. They
were then incubated with anti-rSmStoLP-2 antisera diluted 1:100
in PNT for 2 h at room temperature. After washing five times with
PBS 0.1% Tween 20, pH 7.4 (PBS-T), an Alexa Fluor 488
conjugated anti-rat IgG 1:200 (v:v), 20 mM DAPI (49,6 -
diamidino-2-phenylindole dihydrochloride, Molecular Probes) to
visualize nuclei, and 0.1 mg/ml phalloidin rhodamine (Molecular
Probes) to stain actin microfilaments, were added to PNT solution,
and the samples incubated for 1 h at room temperature. Sections
were washed five times with PBS-T, and then mounted in
Fluorescent Mounting Medium (DakoCytomation). In order to
label the whole parasite, 7-day cultured schistosomula were fixed
in 4% paraformaldehyde in phosphate-buffered saline (PBS) for
1 h on ice, washed with PBS and kept at 4uC until use, the
hybridisation conditions were the same used for adult worm
sections. Rat pre-immune sera were used as negative control.
Images were acquired in a Zeiss LSM 510 Meta confocal system,
attached to a Zeiss Axiovert 100 microscope using a LD-
Achroplan 20x/0.4 or C-Apochromatic 63x/1.2 water immersion
objectives with differential interference contrast.
Measurement of human humoral response to SmStoLP-2
Sera of schistosomiasis patients living in endemic areas in Brazil
were tested by ELISA as previously described [32–34] to measure
the levels of immunoglobulin isoytpes to rSmStoLP-2 protein. For
this assay, 96 well flat-bottom microtiter plates (Nunc) were coated
overnight at 4uC with 100 ml/well of rSmStoLP-2 at a
concentration of 5 mg/ml in 0.1 M carbonate bicarbonate buffer
(pH 9.6). The plates were then blocked with 10% bovine fetal
serum in PBS (pH 7.4) for 2 h at room temperature. Subsequently,
the plates were washed three times with PBS plus 0.05% Tween-
20 (PBS-T). Serum samples diluted 1:50 (IgG) and 1:40 (IgA) in
PBS-T (100 ml/well) were added in duplicate and the plates
incubated for 1 h at room temperature. Peroxidase-labelled anti-
human IgG and anti-human IgA (Sigma) was added at dilutions of
1:10,000 and 1:1000 (100 ml/well), respectively. After 1 h at 37uC,
the plates were washed and orthophenyl-diaminobenzidine plus
0.05% hydrogen peroxide in phosphate citrate buffer (pH 5) was
added (100 ml/well). This mixture was than incubated for 15 min
at room temperature, and the reaction was stopped by addition of
5% H2SO4 (50 ml/well). Absorbance was read at 492 nm using a
microplate reader (Bio-Rad, Hercules. CA, USA). To measure
IgG subclasses, the previous protocol was modified. The serum
dilution was changed based on the isotype to be detected. Serum
samples diluted 1:30 (IgG1), 1:5 (IgG2 or IgG4) and 1:80 (IgG3)
were added to the plates and incubated for 2 h at 37uC, as
previously described [32]. After washing, peroxidase labelled
mouse anti-human antibody was added in each well at
concentrations of 1:1000 (IgG1, IgG3, IgG2 or IgG4), and the
plates were incubated for 16 h at 4uC. The subsequent steps were
identical to those described for the other isotypes.
Cercariae penetration and migration inhibition assay
Cercariae penetration and migration inhibition assays were
adapted from a previously described method for Necator americanus
[35]. Briefly, six aliquots of 100 ml, each containing 100 cercariae
of S. mansoni, were incubated for 1 h at 37uC with 50 ml of sera
from rats immunized with rSmStoLP-2 formulated with Titer-
Max. Sera from rats injected with saline was used as control. To
eliminate any effect of complement, the sera were previously
heated for 30 min at 56uC. After the 1h incubation period, 800 ml
of pond water was added to the samples and the whole volume
(950 ml) was then applied to the shaven abdomen of six
anaesthetized mice (90 mg/Kg of Ketamine and 10 mg/Kg of
Xylazine). The cercariae were allowed to penetrate by the ring
method for 30 min at room temperature. Non-penetrating
parasites were evaluated by counting those that remained on the
surface of the skin, which were collected by removing the
remaining liquid with a pipette and washing the skin twice with
1 ml of PBS. The mean value was considered the percentage of
larval penetration inhibition by the antiserum. Six weeks after
percutaneous penetration, 6 mice per group were sacrificed with a
lethal dose of Ketamine/Xylazine solution. Perfusion fluid (Saline
solution, 500 units/L of heparin) was pumped into the aorta
artery, and perfused worms were collected from the hepatic portal
vein. Adult male and female worms were counted using a
stereomicroscope.
Immunization of mice, challenge infections and parasite
loads
Five to six week-old female C57BL/6 from the Universidade
Federal de Minas Gerais (UFMG) animal facility, were supplied
with food and water ad libitum. Groups of C57BL/6 mice were
lightly anaesthetized (with 45 mg/kg of Ketamine and 10 mg/kg
of Xylazine) and injected subcutaneously in the nape of the neck
with 3 doses, at 15-day intervals, of 25 mg of protein mixed with
Freund’s Complete Adjuvant (Sigma; first dose) or Freund’s
Incomplete Adjuvant (in subsequent doses). In the control group,
SmStoLP-2: A Schistosoma Tegument Protein
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immunization protocol. Challenge infections were performed 2
weeks following the final immunization. Mice were anaesthetized
with 90 mg/Kg of Ketamine and 10 mg/Kg of Xylazine and
exposed percutaneously to 100 cercariae by the ring method on
their shaven abdomens. Six weeks after percutaneous challenge
infections, 10 mice per group were sacrificed and perfused as
described in the cercariae inhibition of penetration assay. The
protection was calculated by comparing the number of worms
recovered from each vaccinated group with its respective control
group, in two independent experiments.
The livers were collected from the same animals fixed in 10%
paraformaldehyde, processed for paraffin embedding and histo-
pathological sections performed using microtome at 6–7 mm and
stained in a slide with hematoxilin-eosin (HE). The number of
granulomas was obtained from the liver sections using 106
objective in a microscope. The area from each liver section was
calculated using capture in scanner followed by analysis in the
KS300 software connected to a Carl Zeiss image analyzer, and the
number of granulomas calculated by the area of the liver.
Humoral response in mice immunized with rSmStoLP-2
Mice were bled from the retro orbital plexus and ELISA was
performed to confirm the titer of specific anti-rSmStoLP-2 IgG,
IgG1 and IgG2a in the serum of immunized animals. Briefly, 96
well flat-bottom microtiter plates (Nunc) were coated overnight at
4uC with 100 ml/well of rSmStoLP-2 at a concentration of 5 mg/
ml in a 0.1 M carbonate bicarbonate buffer (pH 9.6). The plate
was then blocked with bovine fetal serum 10% in PBS for 2 h at
room temperature. Further, the plates were washed three times
with PBS plus 0.05% Tween-20 (PBS-T). One hundred microliters
of each serum diluted 1:100 in PBS-T was added per well and
incubated for 1 h at room temperature. Plate-bound antibody was
detected by peroxidase-conjugated anti-mouse IgG, IgG1 and
IgG2a (Southern Biotechnology) diluted in PBST 1:10,000, 1:5000
and 1:2000, respectively. After 1 h at 37uC, the plate was washed
and orthophenyl-diaminobenzidine plus 0.05% hydrogen perox-
ide in phosphate citrate buffer (pH 5) was added (100 ml/well).
This mixture was then incubated for 30 min at room temperature,
and the reaction was stopped by addition of 5% H2SO4 (50 ml/
well). Absorbance was read at 492 nm using a microplate reader
(Bio-Rad, Hercules, CA, USA). Animals that received PBS with
Freund’s adjuvant were used as negative control.
ELISA detection of IFN-c, IL-4, IL-10 and TNF-a in the
supernatant of spleen cell cultures from mice immunized
with rSmStoLP-2
Cytokine experiments were performed using splenocyte cultures
from individual mice immunized with rSmStoLP-2 plus CFA/IFA
(n=5 for each group). Splenocytes were isolated from macerated
spleens of individual mice 10 days after the third immunization
and washed twice with sterile PBS. The cells were adjusted to
1610
6 cells per well in RPMI 1640 medium (Gibco, CA, USA)
supplemented with 10% FBS, 100 U/ml penicillin G sodium,
100 mg/ml streptomycin sulfate, 250 ng/ml amphotericin B.
Splenocytes were maintained in culture with medium alone or
stimulated with rSmStoLP-2 (25 mg/ml) or concanavalin A
(ConA) (5mg/ml) as previously described [36]. The 96-well plates
(Nunc) were maintained in an incubator at 37uC with 5% CO2.
For cytokine assays, polymyxin B (30 mg/ml) was added to the
cultures and this treatment completely abrogated the cytokine
response to LPS, as previously described [37]. Culture superna-
tants were collected after 48 h of rSmStoLP-2 stimulation for IL-4
and TNF-a analysis and 72 h of rSmStoLP-2 stimulation for IL-10
and IFN-c. The assays for measurement of IL-4, IL-10, IFN-c and
TNF-a were performed using the Duoset ELISA kit (R&D
Diagnostic) according to the manufacturer’s recommendations.
Statistical analysis
Student’s t-test was used and the two-tailed p-value was
calculated to compare experimental and control groups on
challenge infections, antibody profiles and cytokine assays in mice.
For the human humoral response against rSmStoLP-2, the
Kruskal–Wallis test was used to evaluate the significance of the
results of all groups compared to the non-infected (NI). The
Mann–Whitney test was used to evaluate the significance of
antibody measurements obtained between the groups resistant to
S. mansoni reinfection (RR) versus the groups susceptible to
reinfection (SR).
Results
Cloning and molecular characterization of S. mansoni
StoLP-2
The full-length sequence of the S. mansoni cDNA encoding
Stomatin like protein-2 was obtained by PCR from an adult worm
cDNA library with specific oligonucleotides. The resulting full-
length cDNA (GenBank accession EU531730) displays an ORF of
1077 bp, encoding a protein of 358 amino acids with a predicted
molecular mass of approximately 39.5 kDa and an isoelectric
point of 5.83. BlastP comparisons of the deduced S. mansoni protein
sequence to GenBank showed that the best match (E-value=
5610
295) was to Danio rerio hypothetical protein, with 58% identity
and 81% similarity over 355 amino acids. The next best match
was against an unknown S. japonicum protein (probably an
incomplete SLP-2). This was followed by several other SLP-2
proteins including human (58% of identity), therefore we
designated this gene as SmStoLP-2 (since there was already
another gene named as Sm-SLP-2, although not related to
Stomatin like proteins [38]).
SmStoLP-2 contains the stomatin signature sequence (residues
31–189) (outlined by a dashed box in Figure 1), and is recognized
as part of the Pfam SPFH/Band 7 family with an E-value of
1.2610
275. Additionally, searching the S. mansoni genome
(GeneDB) for proteins with Pfam SPFH/Band 7 domains, we
found putative orthologues of H. sapiens stomatin (Band 7), and C.
elegans Mec-2 (Figure 1). We identified a further five schistosome
stomatin-related genes (data not shown).
Human stomatin (Band 7) may associate with membranes via a
hairpin loop (continuous box) with both the N- and C- termini
facing the cytoplasm (Figure 1). This domain is conserved among
several members of the SPFH/Band 7 superfamily, such as C.
elegans MEC-2 and S. mansoni Stomatin and Mec-2, but is absent in
SLP-2 members (Figure 1). We further identify in all SLP-2
sequences putative signal peptides (ranging from 16 to 32 amino
acids at the N-terminal region), which were predicted to be a
mitochondrial targeting sequence (dashed - dotted box). Some
previously recognized stomatin family members, such as human
stomatin, have a consensus sequence for palmitoylation centered
on Cys29 and Cys86 [39], which apparently increase the affinity of
stomatin for the membrane. Further examining the distribution of
potential post-translational modifications of SmStoLP-2, we found
three putative sites for lipid modification (palmitoylation) centered
on Cys11, Cys61 and Cys330 (Figure 1, underlined). Surprisingly,
these palmitoylation sites were not detected in any other analysed
member of the SLP-2 subfamily, except for the S. japonicum
ortholog (data not shown).
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www.plosntds.org 5 February 2010 | Volume 4 | Issue 2 | e597Figure 1. The complete protein sequence of SmStoLP-2 in relation to other members of the stomatin gene family. ClustalX alignment
of the derived amino acid sequence of SmStoLP-2 (EU531730) with S. japonicum StoLP-2 (AAX30477), D. rerio Hypothetical (NP_957325), H.
sapiens SLP-2 (NP_038470), S. mansoni stomatin excluding the first 120 amino acids (GeneDB accession no. Smp_162440), C. elegans Mec-2
excluding the first 50 amino acids (NP_741797), S. mansoni Mec-2 (GeneDB accession no. Smp_122810), H. sapiens stomatin (NP_004090), H.
sapiens SLP-3 (NP_660329), M. musculus SLP-3 (NP_694796), H. sapiens SLP-1 (NP_004800) and C. elegans Unc-24 (NP_501335). Highlighted are
the putative transmembrane domains as predicted by TMHMM (continuous box) absent in all SLP-2, the stomatin signature sequence (dashed box),
mitochondrial targeting sequence as predicted by MitoProt II (dashed and dotted box), sites for palmitoylation (underlined). The regions with high
identity and similarity between stomatin sequences are shown as black and gray columns, according to the Clustal X algorithm.
doi:10.1371/journal.pntd.0000597.g001
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SmStoLP-2 is a member of the stomatin family, grouping it in a
branch with other SLP-2s (Figure S1). Like other stomatins
[13,40,41], it is distantly related to flotillin, prohibitin, and HflK/
C. Two putative flotillin and two putative prohibitins genes were
identified in the S. mansoni genome. As expected, and probably due
to its prokaryotic origin, no orthologues of HflK/C were found
(Figure S1).
Production of recombinant SmStoLP-2
E. coli transformed with pDEST17-SmStoLP-2 showed a band
at 45 kDa when induced with IPTG, which is slightly higher than
the expected molecular mass for rSmStoLP-2 (Figure 2A). The
bacteria were lysed by a French Press and separated into soluble
and insoluble fractions. The insoluble fraction (inclusion bodies)
was shown to contain the majority of the recombinant protein
(Figure 2B, lanes 1, 2). The inclusion bodies were extracted with
8 M urea, refolded by dilution and purified by affinity chroma-
tography on nickel-charged columns through an imidazole linear
gradient from 20 to 500 mM (Figure 2B, lanes 3–8). The fractions
were pooled and dialyzed to remove imidazole, yielding 8.0 mg of
rSmStoLP-2/L culture. Circular Dichroism spectra indicated that
the rSmStoLP-2 contains a regular secondary structure, although
the proportions of secondary structure elements (a-helix and b-
sheet) were not calculated (data not shown).
Analysis of protein expression across the life cycle stages
Extracts were prepared from cercariae, schistosomula, adult
worms, eggs and miracidia stages of S. mansoni and subjected to
immunoblotting with rat anti-rSmStoLP-2 serum, showing
comparable levels of expression in all stages across the parasite
life cycle. Native SmStoLP-2 observed in schistosome extracts,
migrates with a molecular mass higher than that predicted, which
was comparable to rSmStoLP-2 (,49 kDa) (Figure 2C). It is not
known whether an additional smaller band (,47 kDa) could be a
product of post-translational modification, alternative initiation,
protein degradation or alternative mRNA splicing.
Differential tegument extraction of SmStoLP-2 from adult
worms
Extracts from schistosomula and adult worms were separated
into soluble and insoluble fractions and Western blot analysis
revealed SmStoLP-2 to be present in the insoluble fractions in
both stages (Figure 2D). A higher molecular mass band can be
seen in the insoluble fraction of schistosomula, similar to that
observed in the recombinant protein (P). The two most prominent
bands correspond closely to the monomeric and dimeric forms of
the protein at 49 and 98 kDa.
To further characterize the distribution of SmStoLP-2 in S.
mansoni tegument, differential extractions of tegument membrane
proteins were analysed. Western blot using anti-rSmStoLP-2
serum, revealed that SmStoLP-2 was recovered in the first
extraction fraction solubilized with urea/thiourea (Figure 2E),
suggesting SmStoLP-2 to be firmly bound, although non-
covalently, to the tegument membranes.
On the other hand, SmStoLP-2 displays a mitochondrial signal
sequence, which, if functional, may target it to the tegumental
mitochondria. To address this issue, we isolated the tegument and
performed a differential fractionation, separating the membrane
and mitochondrial fractions. The anti-rSmStoLP-2 antibody
recognized the protein in both fractions (Figure 2F). Mitochondrial
enrichment was ascertained using a Mitofusin-1 antibody, which
only detected this protein in the mitochondria-enriched fraction.
SmStoLP-2 is immunolocalized to the tegument of
S. mansoni
Immunolocalization studies using rat serum raised against
rSmStoLP-2 revealed through confocal fluorescence microscopy,
that SmStoLP-2 is mainly expressed in the tegument of the adult S.
mansoni male and female worms and seems to be expressed at lower
levels in the muscle cells of male worms (Figure 3A and E). In an
attempt to localize SmStoLP-2 in relation to the cytoskeletal
tegument components, we used phalloidin-rhodamine as an actin
marker. As shown in Figure 3P, there was some overlap staining
on the muscle layers of adult male worms, revealed by the yellow
signal. In contrast, the green band in the tegument, which
corresponds to the main location of SmStoLP-2, did not seem to
be co-localized with actin (Figure 3P). Additionally, the protein in
male adult worms appears to be located more basally in the
tegument, but it is interesting to note that the green band also
seems to be running around and outside of their dorsal tubercles
(Figure 3P).
Intact schistosomula stained with anti-rSmStoLP-2 and phal-
loidin-rhodamine suggested SmStoLP-2 to be external to the
muscle layers in the tegument, as revealed by the green band
running around and externally to the red band (Figure 3I–K, and
R–T); additionally, the phalloidin-rhodamine internal labelling
confirms that the parasites were well permeabilized (Figure 3J and
M). No staining was observed in male and female sections or intact
schistosomula incubated with naive rat serum (Figure 3C, G and
L). Preliminary experiments indicate that, also in cercariae,
SmStoLP-2 would be located in the evolving tegumental layer.
Immunoglobulin isotype profile of schistosomiasis
patients to rSmStoLP-2
We evaluated by ELISA the specific reactivity of anti-SmStoLP-
2 antibodies in sera of individuals with different status of resistance
and susceptibility to S. mansoni reinfection. The sera of schistoso-
miasis patients, with the exception of the group susceptible to
reinfection (SR), had significant levels of total anti-SmStoLP-2 IgG
as compared to the non-infected group (Figure 4A). Furthermore,
individuals from the group resistant to reinfection (RR) had
increased levels of anti-SmStoLP-2 IgG when compared to
individuals susceptible to reinfection (SR). Regarding IgA,
statistically significant levels of antibodies to rSmStoLP-2 were
observed in the INF and RR groups when compared to the NI
group (Figure 4B). Once more, the RR group produced more anti-
SmStoLP-2 IgA as compared to the SR individuals.
The IgG subclass profile of schistosomiasis patients was
characterized predominantly by IgG1, IgG2 and IgG3 antibody
responses to rSmStoLP-2. Individuals resistant to reinfection (RR)
displayed at least a 2-fold higher level of IgG1, IgG2 and IgG3
anti-SmStoLP-2 antibodies as compared to those susceptible to
reinfection (SR); these isotypes were also significantly higher when
compared to the NI group (Figure 4C). Concerning IgG4, this
antibody isotype was not detected in any of the groups studied.
Inhibition of skin penetration
In an attempt to check if the anti-rSmStoLP-2 antibodies could
impair penetration of cercariae and their survival afterwards, we
performed a skin penetration inhibition assay. As shown in Figure
S2A, the rat anti-rSmStoLP-2 serum inhibited cercarial skin
penetration by 77%, as compared with 40% inhibition by serum
from rats that received saline only (p=0.002). Six weeks after the
infection, we assessed the parasite load in the infected mice; data
revealed that only 12% of the penetrating parasites matured to
adult worms in the group in which cercariae were incubated with
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control serum (Figure S2B). In a typical infection in the murine
model, usually the maturation rate is around 35–40% [42].
Humoral immune response elicited by immunization
with rSmStoLP-2
C57BL/6 mice were immunized with 3 doses of rSmStoLP-2
formulated with Freund’s adjuvant and sera were analyzed by
ELISA at 15, 30, 45, 60, 75 and 90 days for production of anti-
SmStoLP-2 antibodies. Significant titers of specific anti-rSmStoLP-
2 IgG antibodies were detected at all time points, showing a plateau
after the third dose (data not shown). To determine the IgG isotype
profile induced by immunization, specific IgG1 and IgG2a to
rSmStoLP-2 were also analyzed. The levels of specific IgG1 and
IgG2a and the IgG1/IgG2a ratio indicatethat until the second dose
there is a predominant Th2 response and after the third
immunization there occurs a drift towards a more balanced or
Th1-modulated immune response (Table 1).
Figure 2. SDS-PAGE (4%–12%) analysis of cell extracts and fractions from E. coli (BL21DE3) transformed with the pDEST17-
SmStoLP-2, and immunoblotting of protein extracts from S. mansoni stages and fractions using anti-rSmStoLP-2 polyclonal
antibodies. (A) Lanes 1 and 2 represent a clone before and after induction with 1 mM IPTG, respectively; (B) Inclusion bodies were extracted with
urea and denatured protein was refolded by dilution before being purified through Ni
2+-charged column chromatography. Lanes 1 and 2 show the
soluble fraction after lysis and the inclusion bodies after solubilization with 8 M urea, respectively. Lanes 3–5 and 7–9 show the fractions of rSmStoLP-
2-6xHIS-tag fusion protein eluted after Ni
2+ chromatography, Lane 6, MW ladder (kDa); (C) Immunoblotting of S. mansoni extracts from different
stages using anti-rSmStoLP-2 polyclonal antibodies (20 mg of protein were loaded in each lane). Cer – cercariae, Sch – 7-day-old schistosomula, Ad –
adult worms, Egg – eggs, Mir – miracidia. (D) Western blot of soluble (S) and insoluble (I) protein extracts of 10-day-old schistosomula (Sch) and adult
worms (Ad); (E) Detection of SmStoLP-2 in the tegument of S. mansoni adult worms, (1) proteins soluble in urea and thiourea, (2) proteins soluble in
urea, thiourea, CHAPS and SB 3–10, (3) proteins soluble in 2% SDS. (F) Dual targeting of SmStoLP-2 to tegumental membranes and tegumental
mitochondria, TWM, tegument extract without surface membranes, TSM, tegument enriched in surface membranes and TFM, tegument fraction
enriched in mitochondria (20 mg of protein were loaded in each lane), Mfn-1 – is the Mitofusin-1 mitochondrial marker. Arrows indicate the rSmStoLP-
2 and the most reactive bands of native SmStoLP-2 detected in each experiment. Positions of molecular mass standards (kDa) are indicated on the
right or in the center. Positive control (P) contains 50–60 ng of rSmStoLP-2.
doi:10.1371/journal.pntd.0000597.g002
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www.plosntds.org 8 February 2010 | Volume 4 | Issue 2 | e597Figure 3. Immunolocalization of SmStoLP-2 in S. mansoni tegument. Fluorescence confocal microscopy images (Fluor) and corresponding
differential interface contrast (DIC) images of male (A–D, O, and P), female adult worms (E–H), and schistosomulum (I–N and R–T) of S. mansoni are shown.
Polyclonal anti-rSmStoLP-2 and secondary antibody coupled to Alexa 488 (green) were used for fluorescence detection of SmStoLP-2. Serum from naive rat
was used as negative control for male (C), female (G) and schistosomulum (L). DAPI (blue) was used for nucleus localization (E, G, O, and P), and phalloidin
rhodamine (red) was used for actin localization (J, K, M, O, P and T); (M) Diagram of the S. mansoni tegument and an associated cell body (not to scale). Cy:
cytoskeleton; bm: basal membrane; n: nucleus; s: spine (extracted and modified from [43]).
doi:10.1371/journal.pntd.0000597.g003
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In order to investigate the cytokine profile induced by the
rSmStoLP-2 immunization regimen described above, we isolated
splenocytes 10 days after the third immunization. Cytokine
production (IFN-c, TNF-a, IL-4 and IL-10) was measured in
the culture supernatants from in vitro rSmStoLP-2-stimulated
spleen cells of immunized mice. Statistically significant levels of
IFN-c, signature of Th1-type immune response, and TNF-a,a
proinflammatory cytokine, were produced in the stimulated
splenocytes from the rSmStoLP-2-immunized group as compared
with the control (Figure 5A and B). Additionally, high levels of the
modulatory cytokine, IL-10, were also observed (Figure 5C), and
no secretion of IL-4, a Th2 cytokine, was detected (data not
shown). These results indicate that immunization of mice with
rSmStoLP-2 formulated with Freund’s adjuvant induces a Th1-
predominant immune response, with increased levels of IFN-c,
TNF-a and IL-10 and non-detectable levels of IL-4 secretion.
Protection against challenge with cercariae
In order to determine the protective potential of rSmStoLP-2,
immunized mice were challenged with 100 cercariae. The worms
were recovered by perfusion 6 weeks after challenge and results
were expressed as the ‘‘mean worm burden’’ (mean 6 S.D.) and
are summarized in Figure 6. The animals immunized with
rSmStoLP-2 in Freund’s adjuvant showed 30 and 32% reduction
in worm burden against challenge infection in two independent
experiments when compared to the control group. Analysis of egg
counts in the liver did not show a statistically significant reduction
in oviposition.
Discussion
In this report, we have identified SmStoLP-2 as a member of
the stomatin super family, displaying several properties shared
with other SLP-2 proteins and some unique features. The
widespread distribution of the ‘conserved’ SPFH domain across
life kingdoms has been taken as an indication of its ancient origin,
suggesting the common ancestry and functional homology of all
SPFH proteins [13]. However, in a recent review, it has been
proposed that SPFH grouping has little phylogenetic support,
probably due to convergent evolution of its members [41].
Independently of its origin, our phylogenetic analysis of the
deduced SmStoLP-2 protein has grouped it together with human
SLP-2, and SLP-2 from Danio rerio and Xenopus tropicalis, and at
some distance from SLP-1, stomatin (band 7) and SLP-3. We can
highlight the following primary sequence features: 1) SmStoLP-2
lacks an N-terminal hydrophobic domain, similar to other SLP-2
members [9]; 2) SmStoLP-2 and SjStoLP-2 are the unique
members of SLP-2 family, which show putative sites for
palmitoylation, a property that could enhance the hydrophobicity
Figure 4. Isotype profile of sera from schistosomiasis patients
reactive to rSmStoLP-2. Analysis of (A) IgG,(B) IgA and (C) IgG subclass
antibody responses in sera of infected patients (INF), individuals
susceptible to reinfection (SR), resistant to reinfection (RR) and non-
infected individuals (NI). Results are expressed as means of individual
measurements. Error bars indicate S.D. of the means. # Statistically
significant as compared to the non-infected group (P,0.05). * Statistically
significant as compared to the group susceptible to reinfection.
doi:10.1371/journal.pntd.0000597.g004
Table 1. IgG1 and IgG2a immune profile induced by immunization of mice with rSmStoLP-2.
Days
a
15 30 45 60 75 90
IgG1
b 0.8860.33 1.2660.05 1.3160.04 1.2860.05 1.2560.09 1.3260.06
IgG2a
b 0.0260.10 0.1460.12 0.2360.11 0.2760.10 0.2560.08 0.3060.12
IgG1/IgG2a 31.7 9.0 5.6 4.7 4.9 4.3
aDays after the first immunization.
bAbsorbance 492nm.
doi:10.1371/journal.pntd.0000597.t001
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additionally, SmStoLP-2, like all SLP-2 proteins, seems to have a
mitochondrial targeting peptide in the N-terminal region.
The recovery of SmStoLP-2 in the insoluble fraction of parasite
extracts suggests that the protein could be membrane-associated.
Furthermore, solubilization of SmStoLP-2 from tegument mem-
branes after the treatment with the chaotropic agents, urea and
thiourea, indicates that it should be non-covalently bound to the
tegument. It is interesting to note that SmStoLP-2 was not identified
on Braschi’s proteomic study [30], which could be explained based
on the differences in sensitivity of the two methods used to detected
the protein (mass spectrometry and Western blot). Moreover, albeit
not with a quantitative analysis, the fact that SmStoLP-2 protein is
present in the free-living (freshwater) cercariae and miracidia, as
well as in the egg stage, suggests that the protein has other
function(s), not exclusively associated with the tegument, which are
common to both free-living and parasitic stages.
It has been recently proposed that HuSLP-2 may interact with
actin (a cytoskeletal constituent), vav (a small GTPase that
regulates cytoskeleton reorganization) and Nck (an adaptor protein
that links transmembrane and scaffolding molecules to the
cytoskeleton) [23]. The confocal immunofluorescence images of
the parasites confirm the SmStoLP-2 tegument localization and
suggest some weak co-localization with actin, only on muscle
layers of adult male worms. In addition, SmStoLP-2 seems to be
located externally to the muscle layers in the 7-day-old
schistosomulum.
Data from the HuSLP-2 suggests that there are at least two
cellular pools of this protein: one associated with the plasma
membrane and the other with mitochondria [9,11,24]. It is
important to note that the tegumental cytoplasmic layer lying
under the surface membranes, contains small mitochondria [43].
However, confocal immunofluorescence microscopy does not have
sufficient resolution to address this question with confidence. Our
results on the differential fractionation of tegument extracts
analyzed by Western blot addressed this issue and strongly
suggested that SmStoLP-2 also displays a dual targeting, one
associated to the tegument membrane and one to the mitochondria.
As a consequence of the studies in the attenuated cercaria
vaccine model, the schistosomula is believed to be the target of
protective immunity [42]. Given the tegument localization of
SmStoLP-2 in the schistosomula suggested by our immunolocal-
ization results, this molecule should be accessible as an immune
target. In individuals putatively resistant to reinfection (RR), the
antibody response mounted against SmStoLP-2, consisted mainly
of the cytophilic antibodies IgG1 and IgG3, which have
opsonization properties, cell dependent cytotoxicity, and the
ability to activate the classical complement pathway, functions
which could be involved in the resistance to S. mansoni reinfection.
Elevated levels of IgG1, IgG2 and IgG3 have been linked to the
human resistant status for several vaccine candidates, such as,
Sm23, Sm28, Sm14-FABP, Sm29 and TSP-2 [32,44,45].
Concerning IgA levels, investigators have associated the increased
levels of this isotype with resistance to reinfection stimulated by
Sm28GST antigen [46,47], which parallels our results, where high
levels of IgA antibodies to rSmStoLP-2 were observed in patients
which are resistant to reinfection (RR).
Figure 5. Cytokine profile of mice immunized with rSmStoLP-2. Ten days after the last immunization, splenocytes were isolated and assayed
for (A) IFN-c, (B) TNF-a and (C) IL-10 production in response to rSmStoLP-2 (25 mg/ml) or medium as control. The results are presented as mean 6 S.D.
for each group. Significant differences of secreted cytokines after rSmStoLP-2 stimulation or non-stimulated splenocytes are denoted by an asterisk
(p,0.05).
doi:10.1371/journal.pntd.0000597.g005
Figure 6. Scattergram of worm burden from two independent
experiments of mice immunized with rSmStoLP-2 and chal-
lenged with live S. mansoni cercariae. Statistical analyses were
performed with Student’s t-test, *statistically significant (p,0.05)
compared to control group (CFA/IFA).
doi:10.1371/journal.pntd.0000597.g006
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finding that anti-rSmStoLP-2 antibodies inhibits cercariae skin
penetration and migration, suggests that the molecule may have
an important role in larval host entry and in migration through the
tissues until the lungs before reaching the portal hepatic system.
This finding provides further support for testing SmStoLP-2 as a
vaccine candidate against murine schistosomiasis.
In the murine model, rSmStoLP-2 induced high levels of anti-
rSmStoLP-2 IgG after the second immunization and showed a
reduced IgG1/IgG2a ratio at 45 days after the first immunization.
Additionally, we confirmed by cytokine analysis that rSmStoLP-2
immunization elicited a Th1-predominant type of immune
response characterized by production of high levels of IFN-c
and no detection of IL-4. To determine if rSmStoLP-2 conferred
protection against S. mansoni infection, immunized mice were
challenged with cercaria and worm burden analyzed. Immuniza-
tion with rSmStoLP-2 induced a 30-32% worm burden reduction.
A primary obstacle in the research and development of a
schistosomiasis vaccine is a lack of understanding of what type of
immune response should be induced. In the irradiated cercariae
vaccination model, protection can be either based on a Th1, a
Th2, or a mixed Th1/Th2 immune response [48]. However, in
the case of recombinant proteins, Th1 inducing antigens have
been described to induce protection against infection in the mouse
model [36,49–53]. The role of IFN-c in the protective immunity
to schistosomiasis is well described in mice exposed to the
irradiated vaccine and there is compelling evidence that immune
elimination of challenge parasites occurs in the lungs. Since IFN-c
is likely to be required to activate pulmonary macrophages which
may mediate the protective response [54], we could expect that
similar mechanisms would be involved in rSmStoLP-2 protective
immunity.
Recently, HuSLP-2 has been proposed as a potentially useful
target for immunotherapy in humans, since it modulates effector T
cell responses [24]. Thus, down-regulation of HuSLP-2 expression
could be valuable in the course of autoimmune disease treatment,
since it decreases T cell reactivity; alternatively, enhancement of
HuSLP-2 expression could be explored in vaccine development,
since it would increase T cell responsiveness [24]. Given that
orthologs often, but not always, have the same function, it is still
unclear what is the function of SmStoLP-2; it could have an
immunomodulatory role like its human ortholog [24] or could
acquire a different function on the parasite-host interface, like
providing structural scaffolding for the tegument or supporting the
traffic of vesicles to the surface plasma membrane [9], organizing the
peripheralcytoskeletonandassemblyofmultichainreceptors,suchas
ion channels [11,55], or even mechanosensation receptors [18,20].
Further investigations of SmStoLP-2 will be valuable in understand-
ing how the tegument functions as the parasite-host interface.
A critical issue in vaccine design is the use of an appropriate
adjuvant and/or delivery system to induce the suitable immune
response. Experiments are underway investigating rSmStoLP-2
with different adjuvant formulations, which would be suitable for
use in humans. In conclusion, our study showed that SmStoLP-2 is
a novel tegument protein, being recognized by different subclasses
of antibodies in patients resistant and susceptible to reinfection,
and in the light of data obtained from murine studies, protective
properties against schistosomiasis were revealed. We believe that
an ideal vaccine may require the combination of quite a few
antigen targets to induce an effective protection against the
parasite, and SmStoLP-2 could contribute to reach this goal.
Supporting Information
Figure S1 Phylogenetic analysis performed with protein se-
quences showing that SmStoLP-2 is part of the stomatin family.
The sequences accession numbers are: X. tropicalis hypothetical
(GenBank accession no. NP_001004808.1), human prohibitin
(AAP36079), S. mansoni putative prohibitin-1 (GeneDB accession
no. Smp_075210.2), Yeast prohibitin 1 (NP_011648), S. mansoni
putative prohibitin-2 (Smp_075940), Yeast prohibitin 2
(NP_011747), human flotillin-1 (AAP36527), S. mansoni putative
flotillin-1 (Smp_016200.1), human flotillin- 2 (NP_004466), S.
mansoni putative flotillin-2 (Smp_033970), Escherichia coli HflK
(NP_458799), E. coli HflC (NP_418596). (Accession numbers of
the other members are cited in the legend of Figure 1).
Found at: doi:10.1371/journal.pntd.0000597.s001 (0.01 MB PDF)
Figure S2 Inhibition of cercariae skin penetration by rat anti-
SmStoLP-2 antiserum. For these studies, 100 S. mansoni cercariae
were applied in pond water for percutaneous infection and the
number of non-penetrating parasites were counted. The percent-
age inhibition resulting from either rat-anti-SmStoLP-2 antiserum
or antiserum obtained from control rats immunized with saline is
expressed as the mean 6 S.D. of one representative of three
independent experiments.
Found at: doi:10.1371/journal.pntd.0000597.s002 (0.01 MB PDF)
Table S1 Study population.
Found at: doi:10.1371/journal.pntd.0000597.s003 (0.01 MB PDF)
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